Adial Pharmaceuticals (NASDAQ:ADIL) Stock Rating Lowered by Zacks Research

Zacks Research cut shares of Adial Pharmaceuticals (NASDAQ:ADIL) from a strong-buy rating to a hold rating in a research note published on Wednesday morning,Zacks.com reports.

Separately, Wall Street Zen raised Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, July 26th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Adial Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $8.00.

Adial Pharmaceuticals Stock Up 0.0%

ADIL stock opened at $0.3721 on Wednesday. Adial Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $1.30. The stock has a market cap of $8.12 million, a P/E ratio of -0.35 and a beta of 1.00. The business’s 50-day moving average price is $0.38 and its 200-day moving average price is $0.59.

Adial Pharmaceuticals (NASDAQ:ADIL) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. On average, equities research analysts expect that Adial Pharmaceuticals will post -1.53 earnings per share for the current fiscal year.

Institutional Trading of Adial Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Adial Pharmaceuticals by 36.0% in the 4th quarter. Geode Capital Management LLC now owns 61,847 shares of the company’s stock worth $62,000 after acquiring an additional 16,381 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Adial Pharmaceuticals in the 4th quarter worth approximately $48,000. Finally, Citadel Advisors LLC increased its stake in Adial Pharmaceuticals by 63.8% in the 4th quarter. Citadel Advisors LLC now owns 54,508 shares of the company’s stock worth $55,000 after acquiring an additional 21,238 shares during the last quarter. Institutional investors own 16.41% of the company’s stock.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.